We are live on
!
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$193M
1-Year Est. Return
208.51%
This Fund
S&P 500
This Quarter
Est. Return
+43.4%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
–
Cap. Flow
+$84.4M
Cap. Flow
% of AUM
83.47%
Top 10 Holdings %
Top 10 Hldgs %
42.21%
Holding
52
New
52
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dr. Reddy's Laboratories
RDY
|
+$6.02M |
| 2 |
Eli Lilly
LLY
|
+$5.66M |
| 3 |
Cigna
CI
|
+$4.47M |
| 4 |
Structure Therapeutics
GPCR
|
+$3.9M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
+$3.72M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dr. Reddy's Laboratories
RDY
$9.83B
| $6.26M | 6.19% |
+450,000
| New | +$6.02M |
|
|
2
Eli Lilly
LLY
$1.06T
| $5.65M | 5.59% |
+9,700
| New | +$5.66M |
|
|
IMGN
3
DELISTED
Immunogen Inc
IMGN
| $5.54M | 5.48% |
+186,900
| New | +$3.72M |
|
|
4
Cigna
CI
$75.7B
| $4.58M | 4.53% |
+15,300
| New | +$4.47M |
|
5
Celldex Therapeutics
CLDX
$2.78B
| $4.41M | 4.36% |
+111,300
| New | +$3.27M |
|
6
TG Therapeutics
TGTX
$8.5B
| $3.47M | 3.43% |
+203,300
| New | +$2.36M |
|
7
Rhythm Pharmaceuticals
RYTM
$7.04B
| $3.32M | 3.28% |
+72,203
| New | +$2.28M |
|
|
ALPN
8
DELISTED
Alpine Immune Sciences Inc
ALPN
| $3.31M | 3.27% |
+173,500
| New | +$2.41M |
|
9
DexCom
DXCM
$27.2B
| $3.08M | 3.05% |
+24,828
| New | +$2.54M |
|
10
Madrigal Pharmaceuticals
MDGL
$12.5B
| $3.05M | 3.02% |
+13,202
| New | +$2.31M |
|
11
Cytokinetics
CYTK
$11.1B
| $2.91M | 2.88% |
+34,908
| New | +$1.26M |
|
|
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $2.78M | 2.75% |
+73,158
| New | +$1.57M |
|
|
13
Structure Therapeutics
GPCR
$3.61B
| $2.78M | 2.74% |
+68,100
| New | +$3.9M |
|
14
Rocket Pharmaceuticals
RCKT
$358M
| $2.75M | 2.72% |
+91,800
| New | +$2.03M |
|
15
BridgeBio Pharma
BBIO
$16.2B
| $2.63M | 2.6% |
+65,113
| New | +$1.96M |
|
|
ONC
16
BeOne Medicines Ltd
ONC
$33.9B
| $2.31M | 2.28% |
+12,800
| New | +$2.32M |
|
17
Legend Biotech
LEGN
$4.55B
| $2.28M | 2.25% |
+37,900
| New | +$2.4M |
|
18
Penumbra
PEN
$12.5B
| $2.15M | 2.13% |
+8,553
| New | +$1.89M |
|
19
Intuitive Surgical
ISRG
$119B
| $2.14M | 2.12% |
+6,358
| New | +$1.9M |
|
20
Biogen
BIIB
$29.6B
| $2.12M | 2.1% |
+8,200
| New | +$2.01M |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.03M | 2% |
+28,300
| New | +$1.63M |
|
22
Biohaven
BHVN
$2.21B
| $1.95M | 1.92% |
+45,467
| New | +$1.41M |
|
23
Insmed
INSM
$23.3B
| $1.91M | 1.88% |
+61,500
| New | +$1.59M |
|
24
Lantheus
LNTH
$6.75B
| $1.8M | 1.78% |
+29,100
| New | +$1.97M |
|
|
CPRX
25
DELISTED
Catalyst Pharmaceutical
CPRX
| $1.77M | 1.75% |
+105,500
| New | +$1.44M |
|
Similar funds
WWC
JHA
TDWM
MUAMU
DF
BW
SCM
CWRP
Exome Asset Management's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Exome Asset Management, which disclosed 52 positions worth $101M. Its ten largest holdings account for 42% of the portfolio.
Its largest position is Dr. Reddy's Laboratories: 450,000 shares worth $6.26M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Exome Asset Management's largest Q4 2023 buy was Dr. Reddy's Laboratories: 450,000 shares worth $6.26M.
- Exome Asset Management's ten largest holdings make up 42% of its $101M portfolio in Q4 2023.
- Exome Asset Management disclosed 52 positions in Q4 2023, its first 13F filing on record.
Based on Exome Asset Management's 13F filing for Q4 2023, filed 15 Feb 2024.